Coblation Versus Bipolar Diathermy in Management of Refractory Idiopathic Recurrent Anterior Epistaxis in Children.

Launched by ASSIUT UNIVERSITY · Oct 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different methods to treat children who have frequent nosebleeds (called epistaxis) that don't respond to other treatments. The two methods being compared are called coblation and bipolar diathermy. The goal is to see which method is better at stopping the bleeding, how easy each method is to perform, how well the nasal tissue heals afterward, and if either method causes complications like scarring or blockage in the nose.

To participate in this study, children must be between 5 and 18 years old and have experienced at least four nosebleeds in the last month, with at least one bleed per week. They should have already tried other treatments, like ointments or cautery, without success. It's important to note that children with certain bleeding disorders or those who have had previous nasal surgeries cannot take part in this trial. If eligible, participants can expect to receive one of the two treatments, and the doctors will monitor their recovery closely to ensure their safety and track the results.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. A history of repeated unilateral epistaxis with at least four episodes, at least one episode per week during the preceding 4 weeks.
• • 2. Age \> 5 years of age and \< 18 years of age.
• • 3. Failure of topical treatment with an antiseptic ointment, with or without silver nitrate cautery.
• • 4. A Katsanis epistaxis scoring system (ESS) score of 7-10.
• • 5. Bleeding originating from Kiesselbach's plexus, located in the anteroinferior portion of the nasal septum.
• Exclusion Criteria:
• • 1. Patients \< 5 years of age and \>= 18 years of age.
• • 2. Patients with bilateral epistaxis.
• • 3. Patients with bleeding tendencies like: Hemophilia, Leukemia, Idiopathic thrombocytopenic purpura, Von Willebrand disease and Thrombasthenia.
• • 4. Patients with previous nasal surgeries.
• • 5. Patients with hereditary hemorrhagic telangiectasia.
• • 6. Patients with vascular lesions like: angiofibroma, pyogenic granuloma and bleeding polypus.
• • 7. Patients who are unfit for surgery.